HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.

Abstract
Retrospective studies of patients with thrombotic microangiopathies (TMAs) have shown that a deficient activity of von Willebrand factor (vWF)-cleaving protease is involved in thrombotic thrombocytopenic purpura (TTP) but not in the hemolytic-uremic syndrome (HUS). To further analyze the relevance of this enzymatic activity in TMA diagnosis, a 20-month multicenter study of vWF-cleaving protease activity was conducted in adult patients prospectively enrolled in the acute phase of TMA. Patients with sporadic (n = 85), intermittent (n = 21), or familial recurrent (n = 5) forms of TMA (66 manifesting as TTP and 45 as HUS) were included. TMA was either idiopathic (n = 42) or secondary to an identified clinical context (n = 69). vWF-cleaving protease activity was normal in 46 cases (7 TTP and 39 HUS) and decreased in 65 cases (59 TTP and 6 HUS). A protease inhibitor was detected in 31 cases and was observed only in patients manifesting TTP with a total absence of protease activity. Among the 111 patients, mean vWF antigen levels were increased and the multimeric distribution of vWF was very heterogeneous, showing either a defect of the high-molecular-weight forms (n = 40), a normal pattern (n = 21), or the presence of unusually large multimers (n = 50). Statistical analysis showed that vWF-protease deficiency was associated with the severity of thrombocytopenia (P <.01). This study emphasizes that vWF-cleaving protease deficiency specifically concerns a subgroup of TMA corresponding to the TTP entity.
AuthorsA Veyradier, B Obert, A Houllier, D Meyer, J P Girma
JournalBlood (Blood) Vol. 98 Issue 6 Pg. 1765-72 (Sep 15 2001) ISSN: 0006-4971 [Print] United States
PMID11535510 (Publication Type: Case Reports, Journal Article, Multicenter Study)
Chemical References
  • Protease Inhibitors
  • ADAM Proteins
  • Metalloendopeptidases
  • ADAMTS13 Protein
  • ADAMTS13 protein, human
Topics
  • ADAM Proteins
  • ADAMTS13 Protein
  • Adult
  • Female
  • Follow-Up Studies
  • Hemolytic-Uremic Syndrome (blood, diagnosis, therapy)
  • Humans
  • Male
  • Metalloendopeptidases (antagonists & inhibitors, metabolism)
  • Prospective Studies
  • Protease Inhibitors (metabolism)
  • Purpura, Thrombotic Thrombocytopenic (blood, diagnosis, therapy)
  • Remission Induction

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: